751P Survival prognostic and surrogate values of the early modeled CA-125 KELIM in newly diagnosed advanced ovarian cancer: Data from the GCIG meta-analysis group-Reference-Cited by-同舟云学术

751P Survival prognostic and surrogate values of the early modeled CA-125 KELIM in newly diagnosed advanced ovarian cancer: Data from the GCIG meta-analysis group

Published:2021-09 Issue: Volume:32 Page:S744
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Corbaux P.,You B.,Glasspool R.M.,Yanaihara N.,Tinker A.V.,Lindemann K.,Ray-Coquard I.L.,Mirza M.R.,Subtil F.,Colomban O.,Peron J.,Karamouza E.,McNeish I.,Hinsley S.,Kagimura T.,Welch S.,Lewsley L-A.,Paoletti X.,Cook A.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical impact of CA-125 ELIMination rate constant K (KELIM) on surgical strategy in advanced serous ovarian cancer patients;International Journal of Gynecologic Cancer;2024-01-19

2. Confirmation of the utility of the CA-125 elimination rate (KELIM) as an indicator of the chemosensitivity in advanced-stage ovarian cancer in a “real-life setting”;Journal of Gynecologic Oncology;2024

3. Benefit From Fractionated Dose-Dense Chemotherapy in Patients With Poor Prognostic Ovarian Cancer: ICON-8 Trial;JCO Clinical Cancer Informatics;2023-04

4. KELIM score predicts outcome in patients with platinum-resistant/refractory recurrent ovarian cancer;Biomarkers in Medicine;2023-04

5. Mathematical modeling of the early modeled CA-125 longitudinal kinetics (KELIM-PARP) as a pragmatic indicator of rucaparib efficacy in patients with recurrent ovarian carcinoma in ARIEL2 & STUDY 10;eBioMedicine;2023-03